ALTHOUGH there have been significant advances in the therapy of acute brucellosis in the past few years, the incidence of post-treatment relapses has remained a problem. In a previous study reported by us there was a relapse rate of 69% following the administration of any one of three antibiotics for an average period of 12 days.1 Subsequently, efforts to reduce the incidence of relapse proceeded along two lines. One was to prolong administration of a single antibiotic.2 The other was to use a combination of oxytetracycline ("terramycin") and streptomycin, an approach suggested by the apparent synergism between streptomycin and either aureomycin3 or oxytetracycline.4 The present paper reports a study of the latter method in which combined oxytetracycline-streptomycin therapy was administered to 23 patients with acute or subacute brucellosis. The results demonstrate that this form of therapy effects a marked reduction in relapse rate.
MATERIALS AND METHODS
—Of the 23
MAGILL GB, KILLOUGH JH. OXYTETRACYCLINE-STREPTOMYCIN THERAPY IN BRUCELLOSIS DUE TO BRUCELLA MELITENSIS. AMA Arch Intern Med. 1953;91(2):204–211. doi:10.1001/archinte.1953.00240140064005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: